What is ARGX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 45.76B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ARGX?

P/E (TTM) is 20.74 and 52-week range is $568.40 to $925.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ARGX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ARGX?

The company profile lists revenue (TTM) near $8.10B, net income (TTM) near $2.48B, EPS (TTM) near $37.84 when available from the market-data feed. Figures are informational and may lag live markets.

Where is argenx SE based, and what identifiers does Chartloom list?

The company context section lists headquarters in Amsterdam, Noord-Holland, NL, 62.6M shares outstanding, ISIN NL0010832176 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

argenx SE

$ARGX

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

Employees

1,599

Website

www.argenx.com/

IPO

2014-07-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NYSE EURONEXT - EURONEXT BRUSSELS

ISIN

NL0010832176

Headquarters

Amsterdam, Noord-Holland, NL

Shares outstanding

62.6M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

48.35%

Browse other companiesFree AI scores and summaries for more stocks

argenx SE (ARGX) Stock Analysis, Quote & Company Profile